Mirabegron as Medical Expulsive Therapy (MET) for Ureteral Stones and Ureteral Stent Pain

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

July 22, 2017

Primary Completion Date

October 31, 2019

Study Completion Date

October 31, 2019

Conditions
Ureteral ObstructionFlank Pain
Interventions
DRUG

Mirabegron

Randomized 1:1 ratio using a randomized block design, stratified by stone size (≤5 mm versus \>5 mm) and location (upper versus lower ureter). The randomization will be implemented through a database with software designed by the Director of Research Informatics at the Baylor College of Medicine's Dan Duncan Institute of Clinical and Translational Research. It will be a HIPPA-compliant secure database accessible via internet.

OTHER

Placebo

Randomized 1:1 ratio using a randomized block design, stratified by stone size (≤5 mm versus \>5 mm) and location (upper versus lower ureter). The randomization will be implemented through a database with software designed by the Director of Research Informatics at the Baylor College of Medicine's Dan Duncan Institute of Clinical and Translational Research. It will be a HIPPA-compliant secure database accessible via internet.

Trial Locations (1)

77030

Ben Taub General Hospital, Houston

All Listed Sponsors
lead

Baylor College of Medicine

OTHER

NCT02744430 - Mirabegron as Medical Expulsive Therapy (MET) for Ureteral Stones and Ureteral Stent Pain | Biotech Hunter | Biotech Hunter